PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.

Abstract Recent interest has focused on the significance of tumor-infiltrating lymphocytes (TILs) on the efficacies and outcomes of the treatment in breast cancer (BC). Based on the recent international recommendation to standardize the evaluation method, the clinical validity and utility of TILs in patients who underwent neoadjuvant chemotherapy (NAC) were investigated in the present study.
PMID
Related Publications

Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.

Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer.

Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.

Authors

Mayor MeshTerms
Keywords

HER2-enriched

Tumor-infiltrating lymphocytes

neoadjuvant chemotherapy

pathological complete response

triple-negative breast cancer

Journal Title anticancer research
Publication Year Start




PMID- 29599354
OWN - NLM
STAT- MEDLINE
DCOM- 20180412
LR  - 20180412
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 4
DP  - 2018 Apr
TI  - Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by 
      Subtype Using Tumor-infiltrating Lymphocytes.
PG  - 2311-2321
AB  - BACKGROUND/AIM: Recent interest has focused on the significance of
      tumor-infiltrating lymphocytes (TILs) on the efficacies and outcomes of the
      treatment in breast cancer (BC). Based on the recent international recommendation
      to standardize the evaluation method, the clinical validity and utility of TILs
      in patients who underwent neoadjuvant chemotherapy (NAC) were investigated in the
      present study. PATIENTS AND METHODS: TILs were evaluated in 177 patients with BC 
      treated with NAC and subsequent curative surgery. The correlation between TILs
      evaluated according to the standard method and prognosis, including the efficacy 
      of NAC, was investigated retrospectively. RESULTS: In the high-TIL group (n=96)
      compared to the low-TIL group (n=81), triple-negative breast cancer (TNBC)
      (p<0.001) and human epidermal growth factor receptor 2-enriched breast cancer
      (HER2BC) (p=0.040) were significantly more frequent, and the pathological
      complete response (pCR) rate was significantly higher (p=0.003). Among patients
      with TNBC and those with HER2BC, the pCR rate was significantly higher in the
      high-TIL group than in the low-TIL group (p=0.013 and p=0.014, respectively).
      Multivariable analysis also showed that high-TIL status was an independent factor
      predicting favorable prognosis (hazard ratio(HR)=0.24, p=0.023 and HR=0.13,
      p=0.036). Biopsy specimens from local recurrence after successful NAC frequently 
      showed TILs decreased. CONCLUSION: TILs may be a biomarker for predicting
      treatment response to NAC in patients with TNBC and HER2BC. A decrease in TILs
      may also be associated with tumor recurrence.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Asano, Yuka
AU  - Asano Y
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
FAU - Kashiwagi, Shinichiro
AU  - Kashiwagi S
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan [email protected]
FAU - Goto, Wataru
AU  - Goto W
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
FAU - Takada, Koji
AU  - Takada K
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
FAU - Takahashi, Katsuyuki
AU  - Takahashi K
AD  - Department of Pharmacology, Osaka City University Graduate School of Medicine,
      Osaka, Japan.
FAU - Hatano, Takaharu
AU  - Hatano T
AD  - Department of Plastic and Reconstructive Surgery, Osaka City University Graduate 
      School of Medicine, Osaka, Japan.
FAU - Takashima, Tsutomu
AU  - Takashima T
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
FAU - Tomita, Shuhei
AU  - Tomita S
AD  - Department of Pharmacology, Osaka City University Graduate School of Medicine,
      Osaka, Japan.
FAU - Motomura, Hisashi
AU  - Motomura H
AD  - Department of Plastic and Reconstructive Surgery, Osaka City University Graduate 
      School of Medicine, Osaka, Japan.
FAU - Ohsawa, Masahiko
AU  - Ohsawa M
AD  - Department of Diagnostic Pathology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
FAU - Hirakawa, Kosei
AU  - Hirakawa K
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
FAU - Ohira, Masaichi
AU  - Ohira M
AD  - Department of Surgical Oncology, Osaka City University Graduate School of
      Medicine, Osaka, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Biomarkers, Pharmacological)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Biomarkers, Pharmacological/analysis
MH  - Breast Neoplasms/classification/*drug therapy/*immunology/pathology
MH  - Female
MH  - Humans
MH  - Lymphocytes, Tumor-Infiltrating/*drug effects/pathology
MH  - Middle Aged
MH  - Neoadjuvant Therapy
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Receptor, ErbB-2/metabolism
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Triple Negative Breast Neoplasms/drug therapy/immunology/metabolism/pathology
OTO - NOTNLM
OT  - *HER2-enriched
OT  - *Tumor-infiltrating lymphocytes
OT  - *neoadjuvant chemotherapy
OT  - *pathological complete response
OT  - *triple-negative breast cancer
EDAT- 2018/03/31 06:00
MHDA- 2018/04/13 06:00
CRDT- 2018/03/31 06:00
PHST- 2017/12/05 00:00 [received]
PHST- 2018/01/05 00:00 [revised]
PHST- 2018/02/05 00:00 [accepted]
PHST- 2018/03/31 06:00 [entrez]
PHST- 2018/03/31 06:00 [pubmed]
PHST- 2018/04/13 06:00 [medline]
AID - 38/4/2311 [pii]
AID - 10.21873/anticanres.12476 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Apr;38(4):2311-2321. doi: 10.21873/anticanres.12476.